New data show most US patients now stay on Wegovy, Zepbound after a year

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in early 2024 continued their treatment a year later. This marks a significant increase in persistence compared to previous years, potentially driven by improved drug availability, expanded insurance coverage, and enhanced management of side effects by healthcare professionals.